HPN-823

N/A

Report date: 2026/03/19 17:03:31

Base Information

Drug NameHPN-823
Drug Alias NameHPN-823
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Delta-like protein 3Anti-CD3Anti-Albumins
TargetsDelta-like protein 3T cell surface glycoprotein CD3Albumins
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHarpoon Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHarpoon Therapeutics
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A